IBA back on track to offload molecular imaging biz and focus on proton therapy
This article was originally published in Clinica
Executive Summary
Belgian proton therapy firm Ion Beam Applications (IBA) has finalised plans to sell a majority stake in its molecular imaging business, after agreeing to divest the Canadian portion of the unit separately. The move is part of a strategic decision to consolidate the company's business and focus on proton therapy, a spokesperson for IBA told Clinica. "IBA therefore decided to seek a partner to carry out the €100m investment needed to further develop the molecular business' existing platform and future molecules."